Laboratorios Farmaceuticos Rovi, S.A. Stock
Stocks
ROVI
ES0157261019
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Tradegate
09:09:17 2026-10-14 am EDT
|
5-day change | 1st Jan Change | ||
| 58.40 EUR | +1.65% |
|
-1.02% | -8.03% |
| Oct. 05 | Spanish stocks - Factors to watch on Oct 5 | RE |
| Jul. 23 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 |
| Market Cap | 2.94B 3.29B 2.74B 2.48B 4.67B 312B 4.71B 32.81B 12.84B 162B 12.35B 12.08B 521B | P/E 2026 * |
19.4x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 2.93B 3.28B 2.73B 2.48B 4.66B 311B 4.7B 32.71B 12.81B 162B 12.32B 12.05B 520B | EV / Sales 2026 * |
3.78x | EV / Sales 2027 * | 3.21x |
| Free-Float |
31.63% | Yield 2026 * |
1.69% | Yield 2027 * | 2.02% |
| Markets | Quality | ||
|---|---|---|---|
BME
| ROVI | Delayed | |
CBOE
| ROVIe | Real-time | |
|
OTC Markets
| LABFF | Delayed | |
|
Tradegate
| 41L | Real-time | |
|
Deutsche Boerse AG
| 41L | Delayed | |
|
CBOE
| 0ILL | Real-time | |
|
Börse Stuttgart
| 41L | Delayed | |
|
Boerse Muenchen
| 41L | Real-time | |
|
Wiener Boerse
| ROVI | End-of-day quote | |
|
Borsa Italiana
| 1ROVI | End-of-day quote |
Last Transcript: Laboratorios Farmaceuticos Rovi, S.A.
| Jul. 23 | Spanish stocks - Factors to watch on July 23 | RE |
| Feb. 25 | Spanish stocks - Factors to watch on Feb 25 | RE |
| Nov. 06 | Spanish stocks - Factors to watch on Nov 6 | RE |
| 25-03-05 | Spanish stocks - Factors to watch on March 5 | RE |
| 1 day | +1.61% | ||
| 1 week | -1.02% | ||
| Current month | -0.68% | ||
| 1 month | +1.92% | ||
| 3 months | +8.85% | ||
| 6 months | -31.17% | ||
| Current year | -8.03% |
| 1 week | 57.2 |  | 59.15 |
| 1 month | 56.55 | | 60.7 |
| Current year | 53.1 | | 86.7 |
| 1 year | 53.1 | | 86.7 |
| 3 years | 45.52 | | 94.8 |
| 5 years | 35.2 | | 94.8 |
| 10 years | 10.8 | | 94.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2007-07-26 | |
| Director of Finance/CFO | - | 2000-12-31 | |
| Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 2021-07-16 | |
| Director/Board Member | - | 2007-07-26 | |
| Director/Board Member | - | 2007-07-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/23/23 | Buy | Director | 1,000 | 0.0019% | ||
| 4/13/22 | Norbel Inversiones SL
| Sell | Company | 560,690 | 1.0000% | |
| 3/15/22 | Norbel Inversiones SL
| Sell | Company | 2,803,448 | 5.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.65% | -1.02% | -0.09% | +12.85% | 3.29B | |
| -1.36% | +0.78% | +42.36% | +91.48% | 1,040B | |
| -5.73% | -2.42% | +30.23% | +58.50% | 599B | |
| -2.40% | +2.88% | +19.13% | +85.43% | 485B | |
| -2.39% | +0.03% | +65.67% | +36.51% | 350B | |
| +1.54% | +1.36% | +27.50% | +44.72% | 345B | |
| +1.29% | +0.73% | +16.21% | +38.65% | 272B | |
| +0.83% | -1.76% | -6.06% | +9.06% | 244B | |
| -1.13% | +2.54% | +41.19% | +45.32% | 223B | |
| -1.67% | +2.56% | +25.13% | +90.50% | 183B | |
| Average | +0.89% | +2.02% | +26.13% | +51.30% | 374.61B | |
| Weighted average by Cap. | +0.85% | +2.31% | +32.21% | +63.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 774M 867M 721M 654M 1.23B 82.25B 1.24B 8.64B 3.38B 42.78B 3.25B 3.18B 137B | 892M 999M 832M 754M 1.42B 94.83B 1.43B 9.96B 3.9B 49.32B 3.75B 3.67B 158B |
| Net income | 146M 164M 136M 124M 233M 15.54B 234M 1.63B 639M 8.08B 615M 601M 25.94B | 173M 194M 161M 146M 275M 18.37B 277M 1.93B 756M 9.55B 727M 711M 30.66B |
| Net Debt | -8.5M -9.51M -7.92M -7.18M -13.52M -903M -13.62M -94.9M -37.15M -470M -35.73M -34.95M -1.51B | -72.51M -81.17M -67.58M -61.27M -115M -7.7B -116M -810M -317M -4.01B -305M -298M -12.86B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-14 | €58.35 | +1.57% | 23,066 |
| 26-10-13 | €57.45 | -1.79% | 72,375 |
| 26-10-12 | €58.50 | +0.78% | 62,910 |
| 26-10-09 | €58.05 | -0.17% | 56,180 |
| 26-10-08 | €58.15 | -1.44% | 120,294 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ROVI Stock
Select your edition
All financial news and data tailored to specific country editions
